Tanabe Pharma (MTZPY) 16.9800 $MTZPY
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
PR Newswire - Sun Jun 05, 10:01PM CDT
The Global Health Innovative Technology Fund (GHIT Fund) today welcomed ten new funding partnerships that include major global pharmaceutical and biotechnology companies--collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.
JNJ: 115.48 (-1.16), MRK: 55.89 (-1.61), CRM: 80.50 (-1.14)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market h1 2016 - Pipeline Review of Baxalta, CSL Ltd, GeNeuro, Mitsubishi Tanabe Pharma, Pfizer & Teijin Pharma - Research and Markets
BusinessWire - Thu Apr 21, 7:46AM CDT
Research and Markets has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2016" report to their offering.
Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting
PR Newswire - Wed Apr 20, 11:00AM CDT
Mitsubishi Tanabe Pharma Corporation (President & Representative Director: Dr. Masayuki Mitsuka) has presented results from a Phase 3 study of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver, British Columbia. The MCI186-19 study met its primary efficacy endpoint of mean change in the ALS Functional Rating Scale-Revised (ALSFRS-R) at 24 weeks with a frequency of adverse events similar to placebo.
Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 34.22 (-0.53)
Global Methionine Market 2014-2020 - Segmented by Type, Application and Geography
M2 - Mon Feb 01, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/h9lw6n/global_methionine) has announced the addition of the "Global Methionine Market - Segmented by Type, Application and Geography - Trends and Forecasts (2014-2020)" report to their offering. Global Industrial and Institutional cleaning chemical market was currently valued at $3.15 billion in 2014 and is expected to reach $4.2 billion by 2020 showing a compound annual growth rate of 4.9%. Among all the regions in the world Asia Pacific is the largest market for Methionine owing for large dependence of livestock in that region. It is also the fastest growing market during the period 2014-2020 growing at a CAGR of 5.4%. Methionine is basically an alpha amino acid and is a basic building block in the formation of proteins in living beings. The fastest growth is expected to occur in Animal feed industry since Methionine is used in large quantities to promote growth of poultry and livestock, shorten feeding cycle and increase the quantity of lean meat. Methionine is more efficient than fish powder which was previously used as it is very cheap, easily available and very effective. The use of Methionine in Food production and Pharmaceutical industries is also increasing due to its use as nutrition supplements and Intermediate, flavor enhancer, reducing agent respectively. Methionine market is segmented by end user industry which includes Food production, Beverage, Pharmaceutical, Cosmetics, Agriculture, Animal feed and others. It is also segmented by application which includes Animal feed additive, Sodium reducing agent, nutrition supplements, Intermediate in medicine manufacturing, flavor enhancer and Others The key players in Methionine market include Sumitomo Chemical Corporation Limited, Nippon Soda, Bluestar, Aventis S.A, BASF, Jingang Chemical Corporation Limited. DRIVERS: Growth is largely fueled by the increasing demand from developing countries in Asia Pacific and Europe due to their increasing consumption of meat for a protein rich diet. The large population and higher levels of income in these countries adds on to the Methionine market. The increase in genetic technologies which increases the weight of broilers, demand for a broader food portfolio particularly in proteins, and Eco friendly means of extracting Methionine adds to the growth of the market. RESTRAINTS: Rising energy prices serves as a restraint for the growth of market. The promotion of Vegetarianism also decreases the growth of market as people stop eating meat thus the number of feed additives for animals are required less. Volatility in the raw materials also serve as a major drawback to the growth of this market. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Global Methionine market 4. Sources of Methionine 5. Market Dynamics 6. Market Segmentation and Analysis 7. Regional Market Analysis (Market size, growth and forecast) 8. Competitive Landscape 9. Company Profiles - China National BlueStar - Jinzhou Amino Acid Co., Ltd - Evonik Industries - Novus International - Sumitomo Chemical Co., Ltd - Nippon Soda - Bluestar - Mitsubishi Tanabe Pharma Corporation - Zhejiang Chemicals Import & Export Corporation - CheilJedang - ChemChina - Phibro - Suan Farma - Unisplendour - Volzhsky Orgsynthese,JSC - Adisseo - Archer Daniels Midland - Ajinomoto - Arkema - Aventis S.A - BASF - Hifeed - Jilin City - Jingang Chemical Co., Ltd - Kyowa Hokko Bio Co., Ltd - Metabolic Explorer - Roquette - Unisplendour chemical Co., Ltd - Wacker Chemical AG For more information visit http://www.researchandmarkets.com/research/h9...methionine
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 10.10 (-0.83), GSK: 40.33 (-0.24), SYN: 1.78 (-0.09), OPXA: 3.43 (+0.12), FWP: 16.46 (-0.87), TEVA: 52.01 (-0.20), ABBV: 60.01 (-0.89), NVS: 77.91 (+1.02)
Global Hepatitis Drugs Market 2015-2019 - Market Segmentation By Type & MOA
M2 - Mon Dec 21, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/pmwnnp/global_hepatitis) has announced the addition of the "Global Hepatitis Drugs Market 2015-2019" report to their offering. The report forecasts the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019. The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis. Drug manufacturers focus on these countries with the motive of launching new products and penetrating these markets. According to the report, early detection of hepatitis is important in reducing the chances of developing liver infections, which can prevent extensive liver damage. Various government and non-government organizations organize awareness campaigns and other programs to educate people about the disease and therapeutic measures available. Further, the report states that the patent expiration of approved drugs is expected to have an adverse impact on the market, slowing down market growth during the forecast period. Key vendors: - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Novartis - Vertex Pharmaceuticals Other prominent vendors: - Abbvie - Achillion Pharmaceuticals - Bristol-Myers Squibb - Dynavax Technologies - Mitsubishi Tanabe Pharma Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Key marketed drugs PART 07: Market landscape PART 08: Market segmentation by type PART 09: Market segmentation by MOA PART 10: Geographical segmentation PART 11: Market drivers PART 12: Impact of drivers PART 13: Market challenges PART 14: Impact of drivers and challenges PART 15: Market trends PART 16: Vendor landscape PART 17: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/pm..._hepatitis
DVAX: 14.27 (-0.24), JNJ: 115.48 (-1.16), VRTX: 86.73 (-3.68), GILD: 82.65 (-0.86), ACHN: 8.52 (-0.58), MRK: 55.89 (-1.61), GSK: 40.33 (-0.24), BMY: 70.67 (-1.06), NVS: 77.91 (+1.02)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 73.86 (-0.39), BMY: 70.67 (-1.06), GSK: 40.33 (-0.24), ALKS: 41.37 (-0.79), AGN: 235.05 (-2.24), CERCU: 5.03 (-0.56), JNJ: 115.48 (-1.16), ITCI: 37.43 (-1.78), CUR: 0.30 (-0.02)
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
BusinessWire - Mon Dec 14, 6:00AM CST
--- Akebia to Host Conference Call at 8:30 AM Eastern Time Today -
AKBA: 7.95 (-0.61)
World Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Pipeline Review, H2 2015 - 5 Companies & 5 Drug Profiles
M2 - Fri Dec 11, 7:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/zgh3pz/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxalta Incorporated - GeNeuro SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP For more information visit http://www.researchandmarkets.com/research/zgh3pz/chronic
PFE: 34.22 (-0.53), BXLT: 46.02 (-0.18)
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
PR Newswire - Sun Jun 05, 10:01PM CDT
The Global Health Innovative Technology Fund (GHIT Fund) today welcomed ten new funding partnerships that include major global pharmaceutical and biotechnology companies--collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.
JNJ: 115.48 (-1.16), MRK: 55.89 (-1.61), CRM: 80.50 (-1.14)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market h1 2016 - Pipeline Review of Baxalta, CSL Ltd, GeNeuro, Mitsubishi Tanabe Pharma, Pfizer & Teijin Pharma - Research and Markets
BusinessWire - Thu Apr 21, 7:46AM CDT
Research and Markets has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2016" report to their offering.
Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting
PR Newswire - Wed Apr 20, 11:00AM CDT
Mitsubishi Tanabe Pharma Corporation (President & Representative Director: Dr. Masayuki Mitsuka) has presented results from a Phase 3 study of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver, British Columbia. The MCI186-19 study met its primary efficacy endpoint of mean change in the ALS Functional Rating Scale-Revised (ALSFRS-R) at 24 weeks with a frequency of adverse events similar to placebo.
Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 34.22 (-0.53)
Global Methionine Market 2014-2020 - Segmented by Type, Application and Geography
M2 - Mon Feb 01, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/h9lw6n/global_methionine) has announced the addition of the "Global Methionine Market - Segmented by Type, Application and Geography - Trends and Forecasts (2014-2020)" report to their offering. Global Industrial and Institutional cleaning chemical market was currently valued at $3.15 billion in 2014 and is expected to reach $4.2 billion by 2020 showing a compound annual growth rate of 4.9%. Among all the regions in the world Asia Pacific is the largest market for Methionine owing for large dependence of livestock in that region. It is also the fastest growing market during the period 2014-2020 growing at a CAGR of 5.4%. Methionine is basically an alpha amino acid and is a basic building block in the formation of proteins in living beings. The fastest growth is expected to occur in Animal feed industry since Methionine is used in large quantities to promote growth of poultry and livestock, shorten feeding cycle and increase the quantity of lean meat. Methionine is more efficient than fish powder which was previously used as it is very cheap, easily available and very effective. The use of Methionine in Food production and Pharmaceutical industries is also increasing due to its use as nutrition supplements and Intermediate, flavor enhancer, reducing agent respectively. Methionine market is segmented by end user industry which includes Food production, Beverage, Pharmaceutical, Cosmetics, Agriculture, Animal feed and others. It is also segmented by application which includes Animal feed additive, Sodium reducing agent, nutrition supplements, Intermediate in medicine manufacturing, flavor enhancer and Others The key players in Methionine market include Sumitomo Chemical Corporation Limited, Nippon Soda, Bluestar, Aventis S.A, BASF, Jingang Chemical Corporation Limited. DRIVERS: Growth is largely fueled by the increasing demand from developing countries in Asia Pacific and Europe due to their increasing consumption of meat for a protein rich diet. The large population and higher levels of income in these countries adds on to the Methionine market. The increase in genetic technologies which increases the weight of broilers, demand for a broader food portfolio particularly in proteins, and Eco friendly means of extracting Methionine adds to the growth of the market. RESTRAINTS: Rising energy prices serves as a restraint for the growth of market. The promotion of Vegetarianism also decreases the growth of market as people stop eating meat thus the number of feed additives for animals are required less. Volatility in the raw materials also serve as a major drawback to the growth of this market. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Global Methionine market 4. Sources of Methionine 5. Market Dynamics 6. Market Segmentation and Analysis 7. Regional Market Analysis (Market size, growth and forecast) 8. Competitive Landscape 9. Company Profiles - China National BlueStar - Jinzhou Amino Acid Co., Ltd - Evonik Industries - Novus International - Sumitomo Chemical Co., Ltd - Nippon Soda - Bluestar - Mitsubishi Tanabe Pharma Corporation - Zhejiang Chemicals Import & Export Corporation - CheilJedang - ChemChina - Phibro - Suan Farma - Unisplendour - Volzhsky Orgsynthese,JSC - Adisseo - Archer Daniels Midland - Ajinomoto - Arkema - Aventis S.A - BASF - Hifeed - Jilin City - Jingang Chemical Co., Ltd - Kyowa Hokko Bio Co., Ltd - Metabolic Explorer - Roquette - Unisplendour chemical Co., Ltd - Wacker Chemical AG For more information visit http://www.researchandmarkets.com/research/h9...methionine
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 10.10 (-0.83), GSK: 40.33 (-0.24), SYN: 1.78 (-0.09), OPXA: 3.43 (+0.12), FWP: 16.46 (-0.87), TEVA: 52.01 (-0.20), ABBV: 60.01 (-0.89), NVS: 77.91 (+1.02)
Global Hepatitis Drugs Market 2015-2019 - Market Segmentation By Type & MOA
M2 - Mon Dec 21, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/pmwnnp/global_hepatitis) has announced the addition of the "Global Hepatitis Drugs Market 2015-2019" report to their offering. The report forecasts the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019. The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis. Drug manufacturers focus on these countries with the motive of launching new products and penetrating these markets. According to the report, early detection of hepatitis is important in reducing the chances of developing liver infections, which can prevent extensive liver damage. Various government and non-government organizations organize awareness campaigns and other programs to educate people about the disease and therapeutic measures available. Further, the report states that the patent expiration of approved drugs is expected to have an adverse impact on the market, slowing down market growth during the forecast period. Key vendors: - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Novartis - Vertex Pharmaceuticals Other prominent vendors: - Abbvie - Achillion Pharmaceuticals - Bristol-Myers Squibb - Dynavax Technologies - Mitsubishi Tanabe Pharma Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Key marketed drugs PART 07: Market landscape PART 08: Market segmentation by type PART 09: Market segmentation by MOA PART 10: Geographical segmentation PART 11: Market drivers PART 12: Impact of drivers PART 13: Market challenges PART 14: Impact of drivers and challenges PART 15: Market trends PART 16: Vendor landscape PART 17: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/pm..._hepatitis
DVAX: 14.27 (-0.24), JNJ: 115.48 (-1.16), VRTX: 86.73 (-3.68), GILD: 82.65 (-0.86), ACHN: 8.52 (-0.58), MRK: 55.89 (-1.61), GSK: 40.33 (-0.24), BMY: 70.67 (-1.06), NVS: 77.91 (+1.02)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 73.86 (-0.39), BMY: 70.67 (-1.06), GSK: 40.33 (-0.24), ALKS: 41.37 (-0.79), AGN: 235.05 (-2.24), CERCU: 5.03 (-0.56), JNJ: 115.48 (-1.16), ITCI: 37.43 (-1.78), CUR: 0.30 (-0.02)
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
BusinessWire - Mon Dec 14, 6:00AM CST
--- Akebia to Host Conference Call at 8:30 AM Eastern Time Today -
AKBA: 7.95 (-0.61)
World Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Pipeline Review, H2 2015 - 5 Companies & 5 Drug Profiles
M2 - Fri Dec 11, 7:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/zgh3pz/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxalta Incorporated - GeNeuro SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP For more information visit http://www.researchandmarkets.com/research/zgh3pz/chronic
PFE: 34.22 (-0.53), BXLT: 46.02 (-0.18)
